401
Views
19
CrossRef citations to date
0
Altmetric
In Vitro and Animal Studies

Xanthohumol, a hop-derived prenylflavonoid present in beer, impairs mitochondrial functionality of SW620 colon cancer cells

ORCID Icon, , , &
Pages 396-404 | Received 17 Sep 2018, Accepted 22 Oct 2018, Published online: 20 Nov 2018
 

Abstract

Xanthohumol (XN) is a hop-derived prenylflavonoid and have been reported to exhibit anticancer properties in several types of cancer. It presents a great interest against colon cancer due to high exposure of this compound in this tissue. Metastatic SW620 cell line was treated with doses ranging from 0.001 to 10 µM of XN to assess their effects on cell viability and mitochondrial function. At low concentrations, XN had no effect on assays carried out, but high concentration of XN led to a decrease in cell viability. In addition, at 10 μM XN, it gave rise to an increase in ROS production accompanied by a decrease in OXPHOS complexes and sirtuin 1 protein expression levels. These results suggest that XN could act as a mitocan and impairs mitochondrial function.

Disclosure statement

The authors report no conflict of interest.

Additional information

Funding

This work was supported by Fondo de Investigaciones Sanitarias of Instituto de Salud Carlos III under grant PI14/01434 of the Spanish Government confinanced by FEDER-Union Europea (“Una manera de hacer Europa”).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.